Efficacy and safety of rituximab in autoimmune and microangiopathic hemolytic anemia: a systematic review and meta-analysis
ConclusionRTX is more effective than the treatments without RTX for AIHA and MAHA and is well-tolerated.
Source: Experimental Hematology and Oncology - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Clinical Trials | Hematology | Microangiopathic Hemolytic Anemia | Rituxan | Study